Lirimilast structure
|
Common Name | Lirimilast | ||
---|---|---|---|---|
CAS Number | 329306-27-6 | Molecular Weight | 443.25800 | |
Density | 1.619g/cm3 | Boiling Point | 663.2ºC at 760 mmHg | |
Molecular Formula | C17H12Cl2N2O6S | Melting Point | N/A | |
MSDS | N/A | Flash Point | 354.9ºC |
Use of LirimilastLirimilast (BAY 19-8004) is a potent, selective and orally active phosphodiesterase-4 (PDE4) inhibitor with an IC50 value of 49 nM. Lirimilast can be used for the treatment of asthma or chronic obstructive pulmonary disease (COPD). Lirimilast has potently anti-inflammatory properties[1][2]. |
Name | [3-(carbamoylamino)-2-(2,4-dichlorobenzoyl)-1-benzofuran-6-yl] methanesulfonate |
---|---|
Synonym | More Synonyms |
Description | Lirimilast (BAY 19-8004) is a potent, selective and orally active phosphodiesterase-4 (PDE4) inhibitor with an IC50 value of 49 nM. Lirimilast can be used for the treatment of asthma or chronic obstructive pulmonary disease (COPD). Lirimilast has potently anti-inflammatory properties[1][2]. |
---|---|
Related Catalog | |
Target |
PDE4:42 nM (IC50) |
In Vitro | In PDE4 assays Lirimilast (BAY 19-8004) is reported to be 5-fold more potent than Cilomilast and equipotent with CDP-840 using freshly prepared PDE4 from human PMNL[1]. |
In Vivo | Since Lirimilast (BAY 19-8004) is orally active in the guinea-pig at 3 mg/kg and, more critically, in primates at 0.1 mg/kg/day it appears to have a good therapeutic ratio. In addition Lirimilast is found to be 3-fold more potent than Cilomilast when compared in a rat model of lung neutrophilic inflammation[2]. |
References |
Density | 1.619g/cm3 |
---|---|
Boiling Point | 663.2ºC at 760 mmHg |
Molecular Formula | C17H12Cl2N2O6S |
Molecular Weight | 443.25800 |
Flash Point | 354.9ºC |
Exact Mass | 441.97900 |
PSA | 138.07000 |
LogP | 5.46720 |
Index of Refraction | 1.677 |
Lirimilast |
pumafentrine |
UNII-GDK3KY5FCU |
BAY-19-8004 |